Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab + Balstilimab in Early Rectal Cancer
NCT07735624Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in rectal cancer, sponsored by Dana-Farber Cancer Institute. Started Aug 2026; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07735624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735624.